News
-
-
-
PRESS RELEASE
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma and Huadong Medicine sign new collaboration agreement to jointly develop Antibody Drug Conjugates, expanding pipeline with innovative products -
-
-
PRESS RELEASE
EQS-Adhoc: Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma and Huadong Medicine sign a new collaboration agreement to jointly develop new Antibody Drug Conjugates, broadening their existing partnership and combining proprietary technologies -
-
-
PRESS RELEASE
Heidelberg Pharma AG and Huadong Medicine Receive NMPA Approval for Clinical Trial of HDP-101 Combination Therapy in China
Heidelberg Pharma AG and Huadong Medicine receive NMPA approval for Phase Ib/II clinical trial of HDP-101 combination therapy in China. Evaluation of BCMA-targeting ADC in patients with multiple myeloma -